BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sotorasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sotorasib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06249282-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Sotorasib: Phase 1 readout est. (NCT06249282)
DESCRIPTION:Sotorasib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Carfi
 lzomib in Combination With Sotorasib for the Treatment of Patients With KR
 AS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer\nEstimat
 ed primary completion: 24 November 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06249282
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Sotorasib: Phase 1 readout est. (NCT04185883)
DESCRIPTION:Sotorasib\, phase 1.\nStudy: Sotorasib Activity in Subjects Wit
 h Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)\nEstimat
 ed primary completion: 17 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04625647-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sotorasib: Phase 2 readout est. (NCT04625647)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Testi
 ng the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced 
 Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04625647
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Sotorasib\, phase 2\, Colorectal Cancer.\nStudy: Pre-operative 
 Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (
 UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012031-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Sotorasib: Phase 1/2 readout est. (NCT07012031)
DESCRIPTION:Sotorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sot
 orasib in Combination With Trastuzumab Deruxtecan for the Treatment of Loc
 ally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C M
 utation\nEstimated primary completion: 14 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07012031
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920356-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sotorasib: Phase 3 readout est. (NCT05920356)
DESCRIPTION:Sotorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab 
 Platinum Doublet Combination as a Front-Line Therapy in Participants With 
 Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers 
 (CodeBreaK 202)\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05920356
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05815173-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sotorasib: Phase 1 readout est. (NCT05815173)
DESCRIPTION:Sotorasib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ladar
 ixin With Sotorasib in Advanced NSCLC\nEstimated primary completion: Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0581517
 3
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582771-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sotorasib: Phase 2 readout est. (NCT06582771)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Sotorasib in People With Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sotorasib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06582771
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804824-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Sotorasib: Phase 1 readout est. (NCT06804824)
DESCRIPTION:Sotorasib\, phase 1.\nStudy: A First-in-Human (FIH) Study to Ev
 aluate the Safety and Tolerability of VVD-159642 in Participants With Adva
 nced Solid Tumors\nEstimated primary completion: 1 August 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06804824
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118854-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05118854)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carb
 oplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamo
 us Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation\nEstimated prima
 ry completion: 20 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sotorasib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05118854
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Sotorasib: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Sotorasib\, phase 1\, Colorectal Cancer.\nStudy: ASCEND-CRC: Pr
 ofiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic
  Colorectal Cancer\nEstimated primary completion: 14 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06659341-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sotorasib: Phase 1 readout est. (NCT06659341)
DESCRIPTION:Sotorasib\, phase 1.\nStudy: A Phase I Study of BAY3498264 Give
 n Together With Sotorasib in Participants Who Have Advanced Solid Cancers 
 With Specific Genetic Changes Called KRASG12C Mutation\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sotorasib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06659341
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631249-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05631249)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sotor
 asib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects W
 ith Mutated KRAS p.G12C\nEstimated primary completion: 12 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05631249
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398094-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05398094)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Clini
 cal Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients a
 nd Ineligible for Chemo-radiotherapy\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 98094
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807619-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sotorasib: Phase 1 readout est. (NCT06807619)
DESCRIPTION:Sotorasib\, phase 1.\nStudy: A Study of Sotorasib in People Wit
 h Brain Tumors\nEstimated primary completion: January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06807619
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172919-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07172919)
DESCRIPTION:Sotorasib\, phase 2.\nStudy: A Rollover Study Evaluating Sotora
 sib With or Without Panitumumab in Participants With KRAS p.G12C Mutation\
 nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07172919
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06252649-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Sotorasib: Phase 3 readout est. (NCT06252649)
DESCRIPTION:Sotorasib\, phase 3\, Colorectal Cancer.\nStudy: Study of Sotor
 asib\, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-
 awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer Wi
 th KRAS p.G12C Mutation\nEstimated primary completion: 25 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06252649
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543172-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07543172)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: CIMAv
 ax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced\, KRAS G12C 
 Mutated Non Small Cell Lung Cancer\nEstimated primary completion: 1 June 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07543172
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sotorasib: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Sotorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 2
 -part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion:
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/soto
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07563738
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124884-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07124884)
DESCRIPTION:Sotorasib\, phase 2\, Colorectal Cancer.\nStudy: 5-fluorouracil
  Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First
 -line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherap
 y With Advanced Unresectab\nEstimated primary completion: 30 June 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07124884
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892054-1987@assetmemo.bio
DTSTAMP:20261121T004938Z
DTSTART;VALUE=DATE:20300808
DTEND;VALUE=DATE:20300809
SUMMARY:Sotorasib: Phase 1 readout est. (NCT06892054)
DESCRIPTION:Sotorasib\, phase 1.\nStudy: Sotorasib Combined With First-line
  Chemotherapy for Advanced Pancreatic Adenocarcinoma\nEstimated primary co
 mpletion: 8 August 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sotorasib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06892054
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
